OPERF
CTKB icon

Oregon Public Employees Retirement Fund’s Cytek Biosciences CTKB Stock Holding History

Oregon Public Employees Retirement Fund’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Hold
25,175
– – ﹤0.01% 1497
2025
Q4 		$127K Buy
25,175
+500
+2% +$2.32K ﹤0.01% 1478
2025
Q3 		$85.6K Buy
24,675
+1,200
+5% +$4.5K ﹤0.01% 1504
2025
Q2 		$79.8K Sell
23,475
-475
-2% -$1.58K ﹤0.01% 1500
2025
Q1 		$96K Sell
23,950
-600
-2% -$3.11K ﹤0.01% 1497
2024
Q4 		$159K Sell
24,550
-500
-2% -$2.98K ﹤0.01% 1452
2024
Q3 		$139K Buy
25,050
+1,800
+8% +$10.2K ﹤0.01% 1473
2024
Q2 		$130K Sell
23,250
-3,200
-12% -$19.2K ﹤0.01% 1470
2024
Q1 		$177K Sell
26,450
-2,500
-9% -$19.8K ﹤0.01% 1443
2023
Q4 		$264K Sell
28,950
-500
-2% -$3.15K ﹤0.01% 1398
2023
Q3 		$163K Buy
29,450
+4,500
+18% +$36.1K ﹤0.01% 1606
2023
Q2 		$213K Buy
+24,950
New +$224K ﹤0.01% 1575

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oregon Public Employees Retirement Fund's CTKB Position: Q1 2026 in Review

Oregon Public Employees Retirement Fund held its Cytek Biosciences (CTKB) position steady in Q1 2026 at 25,175 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Oregon Public Employees Retirement Fund first reported a position in CTKB in Q2 2023 and has held it in 12 quarters since. The position peaked at $264K in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Oregon Public Employees Retirement Fund held 25,175 shares of Cytek Biosciences worth $110K as of Q1 2026.
  • Oregon Public Employees Retirement Fund left its Cytek Biosciences share count unchanged in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Oregon Public Employees Retirement Fund's portfolio in Q1 2026, its #1497 holding.
  • Oregon Public Employees Retirement Fund first reported a position in Cytek Biosciences in Q2 2023 and has held it in 12 quarters since.
  • Oregon Public Employees Retirement Fund's Cytek Biosciences position peaked at $264K in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Oregon Public Employees Retirement Fund's 13F filing for Q1 2026, filed 29 Apr 2026.